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Department of Psychology, erasmus 
School of Social and Behavioural 
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Abstract: This systematic review aimed to evaluate the efficacy of neurofeedback (NF) 
compared to stimulant medication in treating children and adolescents with attention-deficit/
hyperactivity disorder (ADHD). Included in this review are eight randomized controlled trials 
that compared an NF condition, either alone or combined with medication, to a medication 
condition, which was mainly methylphenidate. Outcome measures included behavioral assess-
ments by parents and teachers, self-reports, neurocognitive measures, electroencephalogram 
power spectra and event-related potentials. When only trials are considered that include 
probably blinded ratings or those that are sham-NF or semi-active controlled or those that 
employed optimally titration procedures, the findings do not support theta/beta NF as a 
standalone treatment for children or adolescents with ADHD. Nevertheless, an additive treat-
ment effect of NF was observed on top of stimulants and theta/beta NF was able to decrease 
medication dosages, and both results were maintained at 6-month follow-up. This review 
concludes that the present role of NF in treating children diagnosed with ADHD should be 
considered as complementary in a multimodal treatment approach, individualized to the 
needs of the child, and may be considered a viable alternative to stimulants for a specific 
group of patients. Particularly patients with the following characteristics may benefit from 
NF treatment: low responders to medication, intolerable side effects due to medication, 
higher baseline theta power spectra and possibly having no comorbid psychiatric disorders. 
Future research should prioritize the identification of markers that differentiate responders 
from nonresponders to NF treatment, the potential of NF to decrease stimulant dosage, the 
standardization of NF treatment protocols and the identification of the most favorable neu-
rophysiological treatment targets.
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Introduction
The prevalence of attention-deficit/hyperactivity disorder (ADHD) in children and 
adolescents is estimated to be 5%, making it one of the most common diagnoses in 
children.1 In fact, prevalence of core symptoms, which comprise attention deficiency, 
hyperactivity and impulsivity, is estimated to be 20%, as evaluated by reports of 
teachers and parents.2 However, concerns have been raised regarding the overdiagnosis 
and overmedication of ADHD and its adverse effects on children.3,4 On the other hand, 
other evidence suggests underdiagnosis of ADHD is another cause for concern.5 Two 
systematic reviews show that untreated patients with ADHD have poor long-term 
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outcomes, including addictive behavior and problems in 
academic performance, interpersonal relationships and 
overall functioning.6,7
Currently, the first line of treatment for children and 
adolescents diagnosed with ADHD from age 6 years onward 
consists of psychostimulant medication, which is primarily 
methylphenidate (MPH).8 There is substantial evidence 
for MPH improving functioning on symptom domains 
of attention, impulsivity and social behavior, with high 
effect sizes ranging from 0.63 to 0.85.9 Some limitations of 
psychostimulants, however, are the short duration of treat-
ment effects, achieving no or only partial response in some 
patients, the lack of achieving long-term remission and 
short-term adverse effects such as fatigue, nausea and loss 
of appetite.1,10 Further issues include the significant portion 
of parents who have nondrug treatment preferences and the 
compliance of stimulants.11 Long-term adverse effects are yet 
to be identified, but there is increased awareness about their 
potential for adverse cardiovascular effects and suppression 
of growth in children.12,13
In response to these shortcomings, researchers have 
increasingly focused on different forms of treatment for 
children and adolescents with ADHD. Neurofeedback (NF), 
or electroencephalogram (EEG) biofeedback, is a relatively 
new, noninvasive approach for treating multiple brain-related 
conditions. Epilepsy has been one of the first therapeutic 
applications of NF that has been subject to extensive NF 
research. More conditions in which NF is being used include 
ADHD, learning disabilities, strokes, head injury, insom-
nia, depression, obsessive–compulsive disorder and drug 
addiction.14 NF attempts to normalize the disrupted brain 
waves that are associated with these conditions by means of 
repeated training based largely on operant conditioning.15 
Although the overall working mechanisms of NF are partially 
explained by operant conditioning principles, the implications 
of how such training may influence biological processes at the 
hormonal or cellular level remains not fully understood. The 
assumption is that brain waves reflect neural functions, and 
that training in brain waves may improve neural functions, 
subsequently leading to improvements in ADHD symptom 
domains and behavior. NF is thus a method that assists 
subjects to control their brain waves consciously. The most 
frequently used type of NF used to treat ADHD is frequency/
power NF, which is used to change the amplitude or speed of 
specific brain waves in particular brain locations, such as the 
frontal or parietal lobes. Another type of NF that is sometimes 
used to treat ADHD is slow cortical potential (SCP)-NF, 
which improves the direction of SCPs. Other types of NF 
include hemoencephalographic NF, functional MRI NF, low-
resolution electromagnetic tomography and near-infrared 
spectroscopy NF, which are used for the treatment of various 
disorders.
One of the most consistent findings reported in the 
qualitative EEG literature on ADHD are those of increased 
anterior absolute power theta activity.16–18 The literature 
is less consistent about reduced absolute beta in ADHD, 
although reduced relative beta has been reported more 
often.16–18 Despite these consistent findings, previous studies 
have shown a low diagnostic value of excessive theta or 
theta/beta ratio, with accuracies below 65%.16,19,20 Although 
detailed discussion is beyond the scope of this paper, these 
EEG differences have contributed to the development of 
different NF treatment protocols in ADHD. The goal of 
theta/beta NF is to reduce brain activity in the theta band 
and to increase its activity in the beta band (or to decrease 
the theta/beta ratio), which aims to improve inattention.15 
SCP-NF targets the decreased contingent negative variation 
amplitudes. Sensorimotor rhythm (SMR) is a form of beta 
protocol that is also used in ADHD, targeting frequencies 
in the range of 12–15 Hz to address hyperkinetic behavior. 
Other protocols such as alpha, delta and gamma have found 
less robust results in the context of ADHD and are used more 
frequently in the treatment of other disorders.
A substantial amount of research has been conducted on 
the efficacy of NF compared to placebo, semi-active controls 
or sham-NF in the treatment of ADHD. The meta-analysis of 
Arns et al21 used studies with different designs (controlled/
noncontrolled and randomized/nonrandomized), showing 
large effect sizes for NF on impulsivity and inattention, but 
medium to low effect sizes on hyperactivity, and concluded 
that NF can be considered “Efficacious and Specific”. Three 
randomized controlled trials (RCTs) have shown NF to be 
superior to a semi-active control condition, such as electro-
myographic biofeedback, which can be regarded as a credible 
sham control.21 Moriyama et al22 reported medium to large 
effect sizes when assessing only nonrandomized trials, but 
medium to low effect sizes when only randomized trials were 
considered. Three randomized sham-NF controlled trials 
found no treatment differences between NF and sham-NF 
in children with ADHD. However, some authors argued that 
the negative results from these sham-NF controlled trials 
are in part due to effective blinding, using suboptimal treat-
ment protocols and not employing adequate conditioning 
procedures.22 In short, based on the few randomized, semi-
active controlled trials, NF seems moderately efficacious 
in treating children with ADHD, but the exact role of NF 
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remains unclear in part due to the contrasting results from 
controlled trials.
A particularly relevant question for clinical practice is 
how NF compares to stimulant medication. In recent years, 
several head-to-head RCTs have been published. However, 
the systematic reviews and meta-analyses that have been 
published on NF in relation to ADHD have focused primar-
ily on studies comparing NF to nonpharmacological controls 
(placebo, semi-active controls or sham-NF). To date, one 
meta-analysis21 and two reviews22,23 have incorporated a 
section focused on trials comparing NF to stimulants. How-
ever, due to the lack of trials that compared NF to stimulants 
at the time, the authors noted that for hyperactivity and inat-
tention, there was not enough data available for a valid com-
parison between MPH and NF.21 With the data of five studies 
that compared NF to MPH, the meta-analysis did not find 
any differences for impulsivity ratings, although those studies 
were not randomized or blinded.21 The review of Moriyama 
et al22 reported three trials that compared NF to stimulants, 
none of which found NF to be inferior to stimulants, but these 
trials were nonrandomized and two of them only focused 
on neurophysiological outcomes. The systematic review 
of Holtmann et al,23 available only in German, showed 
encouraging results for NF and included three controlled 
studies that compared NF to MPH, but emphasized the need 
for further controlled studies with sufficient sample sizes, 
appropriate measures and follow-up. The more recent review 
of Holtmann et al24 included three head-to-head RCTs (NF 
vs stimulants). Out of these three RCTs, two found no dif-
ference in efficacy between NF and medication,25,26 whereas 
one found NF to be inferior to medication.27 Since 2013, 
eight more studies have been published that compare NF to 
MPH in a randomized controlled design, including several 
follow-up publications, that are not included in the currently 
available reviews. In view of the contrasting results from the 
first comparison RCTs and the emergence of more recent 
RCTs, a more up-to-date review is warranted. To date, this 
is the only systematic review that is specifically aimed at 
RCTs comparing NF to stimulants in children or adolescents 
with ADHD.
Materials and methods
The literature was searched for studies that compared 
frequency/power NF to MPH (or other stimulants) in 
children with ADHD. A search in the electronic PubMed/
MEDLINE database was performed with the following 
inclusionary terms: (“ADHD” or “ADD” or “attention defi-
cit hyperactivity disorder” or “attention deficit disorder”) 
and (“neurofeedback” or “NFB” or “EEG biofeedback” 
or “slow cortical potentials” or “SCP” or “neurotherapy” 
or “brainwave training” or “theta beta” or “sensorimotor 
rhythm” or “SMR”) and (“methylphenidate” or “stimulant 
medication” or “psychostimulants” or “dexamphetamine” 
or “atomoxetine”). Studies were only included if: 1) the 
study design was an RCT; 2) the article was peer reviewed 
and 3) the language of publication was English. There 
were no exclusion criteria based on comorbidity and 
comedication.
As shown in Figure 1, this search yielded 76 abstracts, 
which were all screened. An abstract was selected when it 
contained both NF and stimulant medication as interventions 
for at least two separate groups of children or adolescents 
diagnosed with ADHD and compared their efficacy on treat-
ing ADHD, measured either through subjective or objective 
outcome measures. This selection resulted in 15 abstracts. 
After this process, the full-text articles of the remaining 
abstracts were screened and assessed for inclusion. Two 
studies were excluded due to the study design not including 
randomization. One article was excluded since this was an 
identical reprint of another. The remaining 12 articles were 
included in this review. While screening the full-text articles, 
cross-references were checked and a forward search was done 
to identify any missing articles. Of the remaining 12 articles, 
several were related by sharing the same sample and group of 
authors, but differed in outcome measures or were follow-up 
assessments. These were clustered together, leading to eight 
distinct RCTs (Table 1).
Results
Table 1 gives an overview of the eight RCTs (12 publications) 
that are included in the current review. All studies included 
children and/or adolescents diagnosed with ADHD. The age 
range of participants was 6–18 years in eleven studies and 
12–24 years in one study. The number of sessions of NF 
treatment ranged from 20 to 40, and the duration per ses-
sion ranged from 25 to 50 minutes across the studies. The 
sample sizes ranged from n=32 to n=130. Six studies used a 
theta/beta protocol, whereas two studies used a theta/SMR 
protocol. Stimulant medication usage during NF treatment 
was allowed in four studies; hence, these studies compared 
a combination condition (NF and medication) to a medica-
tion only condition, and one of these also included an NF 
only condition. Four studies compared NF as a standalone 
intervention to a medication condition. The most common 
outcome measures were behavioral assessments by parents 
and teachers, employed by seven studies. Other outcome 
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measures were self-reports, neurocognitive tests, EEG 
parameters and event-related potentials (ERPs). Three studies 
included a 6-month follow-up.
With regard to psychiatric comorbidity, two studies 
excluded psychiatric comorbidity26,28 while all other studies 
allowed psychiatric comorbidity. Of the studies that allowed 
comorbidity, only four studies reported the data of differ-
ent comorbid disorders in the sample.27,29–31 The most com-
mon comorbid disorders were oppositional defiant disorder, 
conduct disorder, mood disorders, anxiety disorders and 
autism spectrum disorders. All studies excluded patients 
with IQ scores below 70 or 80.
Contrasting results have been found. Of the studies that 
compared NF alone to stimulant medication, two studies 
showed improvements in both treatment groups with no 
significant differences between NF and stimulants on the 
outcome measures,25,26,32,33 whereas three studies found 
stimulant medication to be superior to NF.27,30,31,34,35 Of 
the studies that compared combination treatment (NF and 
stimulant medication) to stimulant medication, two studies 
found combination treatment to be superior to stimulant 
treatment only,33,36 whereas one study showed no difference 
in efficacy between treatments.29 Notably, in that study, 
the combination treatment comprised NF and treatment 
as usual, which includes both medication and behavioral 
interventions.29 All three studies that included 6-month 
follow-up found NF to be equally effective to stimulants at 
6-month follow-up.26,33,36
The following results regard subjective outcome mea-
sures (ie, behavioral assessments, self-reports). Three out of 
six studies that used behavioral assessments by parents and 
teachers found NF to reduce ADHD symptoms (inattention, 
hyperactivity) similar to stimulant medication, with effects 
maintained at 6-month follow-up.25,26,33 One study found 
the combination treatment to be superior to medication in 
reducing ADHD symptoms.36 On the other hand, two studies 
found medication to be superior to NF in reducing ADHD 
symptoms based on behavioral assessments by parents and 
teachers.27,31 The two studies that used self-reports found 
favorable results for NF treatment, with effects maintained 
at 6-month follow-up.32,33,36
The following results regard objective outcome measures 
(ie, neurocognitive tests, EEG parameters and ERPs). Of the 
two studies that used neurocognitive outcome measures, 
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Figure 1 PRISMA flow diagram of study selection.
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Bink et al29 found equal improvements on neurocognitive 
tests between combination treatment and medication only, 
whereas Geladé et al30 found medication to improve signifi-
cantly compared to NF. Four studies used brain functions 
(EEG spectra, ERPs) as outcome measures. In the study 
of Ogrim and Hestad,27 posttreatment theta activity did not 
differ between NF and stimulants. In the study of Janssen 
et al,34 both the NF group and the medication group showed 
significant reduction in theta power in the “eyes open” condi-
tion, but only the medication group showed reduction in theta 
power in the “active task” condition. In another publication, 
the same authors showed that the P3 no go ERP amplitudes 
increased only in the medication group.35 The study of Lee 
and Jung28 found reduction in theta power in the combina-
tion treatment. The study of Li et al36 found that the average 
dominant probability of alpha waves decreased significantly 
in the combination treatment and was maintained at 6-month 
follow-up. An additional outcome was change in medica-
tion dosage after NF treatment, reported by two studies:26,36 
the study of Li et al36 showed significant reduction of MPH 
dosage at 6-month follow-up and the other study did not find 
statistical differences.26
Discussion
The present review examined eight RCT studies that com-
pared NF treatment (six theta/beta, two theta/SMR), either 
alone or combined with stimulant medication, to stimulant 
medication in the treatment of children or adolescents with 
ADHD. Noteworthy is the change in medication dosage after 
NF treatment reported by two studies. Medication dosage 
was reduced when NF was given in conjunction with MPH, 
implying that NF may be particularly useful for low respond-
ers to single-drug treatment or children who experience side 
effects with MPH.25,36 In the study of Li et al36 (n=64), the 
combination treatment showed significant reduction of MPH 
dosage at 6-month follow-up. In the study of Meisel et al,26 
33% of NF patients (4/12) maintained improvements after 
6-month follow-up and did not require further medication, 
while 67% (8/12) was medicated after NF treatment. The 
relatively small sample size of this study (n=23) may have 
contributed to a lack of statistical significance. Other studies 
in this review did not report data of medication use or dosage 
after NF treatment. Future studies should further explore the 
possibility of NF decreasing medication dosage.
Similar to the reviews of Holtmann et al24 and Moriyama 
et al,22 the current review has found contrasting results. The 
review of Moriyama et al, which focused on studies that 
assessed the efficacy of NF, found that most non-RCTs 
reported medium to large effect sizes, whereas the effects 
were less robust when only RCTs were considered.22 The 
meta-analysis of Cortese et al37 reported significant effects 
for proximal ratings on ADHD symptoms, but failed to find 
significant effects when probably blinded ratings were the 
outcome or the trials included active/sham controls, which 
persisted when only frequency band training trials were 
analyzed. Some factors that may account for the contrasting 
results include different NF protocols, titration procedures, 
washout procedures, patient selection, sample sizes, number 
of treatment sessions and exclusion of comorbidity. Another 
limitation is that studies were not powered to detect differ-
ences. NF treatment protocols are currently not standard-
ized in ADHD, which likely plays a role in the contrasting 
study results; also, the frequency band protocols may not be 
the most suitable targets for NF in ADHD. One frequently 
recurring point of debate concerns whether behavioral 
improvements are the result of specific NF treatment effects 
or nonspecific treatment effects, that is, placebo effects, such 
as therapist engagement or personal motivation. These may 
have contributed to the contrasting results found in the current 
RCT studies, despite the use of randomization. A better moti-
vation to change ADHD may be particularly relevant due to 
the fact that NF is an intense treatment that may be facilitated 
through supportive parents and the child’s own motivation. 
Clinically, pretreatment motivation of patient or parents may 
be useful as a potential predictor for NF treatment response. 
Future research should identify the exact role of motivation 
by parents and children in NF treatment outcome.
Some authors have suggested that these nonspecific 
effects should be addressed by employing a double-blind 
sham-NF controlled study design. The only RCT in the 
present review that used a double-blind design found the 
combination of NF and medication to be superior to medica-
tion with nonfeedback training, that is, sham-NF, supporting 
the additive treatment effect of NF to medication.36 Although 
a double-blinded study design seems promising, employing 
such a design has practical limitations in the case of NF. For 
example, in addition to controlling neurophysiological param-
eters, psychosocial factors must also be controlled, such as 
perceptibility, controllability, motivation and learnability.38 
Another potential route to overcome nonspecific effects can 
be found in the studies using longer follow-up durations, 
since it is less likely for nonspecific effects to last over longer 
periods. Two RCTs included in the current review found that 
treatment effects were maintained at 6-month follow-up, 
while the double-blind sham-NF controlled trial found that 
medication dosage was significantly increased in the sham 
condition.36 It would be relevant for future studies to inves-
tigate how the specific effects of NF compare to medication 
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treatment effects by using a double-blind study design with 
four treatment arms: NF+medication, NF+placebo, sham-
NF+medication and sham-NF+placebo.
An alternative method for overcoming the issues regard-
ing the blinding procedures in NF studies is by placing more 
weight on the teacher ratings when comparing the results of 
teacher and parent ratings, as teacher ratings are considered 
to be probably blind.37,39,40 Out of the five RCTs that reported 
both teacher and parent ratings, three studies did not find any 
differences in parent or teacher ratings.27,33,36 The other two 
studies did find differences in treatment effects in favor of 
parental ratings. One of these found larger improvements on 
inattention according to parents compared to teachers after 
theta/beta training.26 The other study reported that, in contrast 
to parents, teachers reported no improvements in all ADHD 
symptoms in both the theta/beta group and semi-active con-
trols, while both parents and teachers reported improvements 
in the medication group.30,31 These findings suggest that 
parental expectations and investment may contribute to the 
parent-reported improvements on ADHD symptoms, which 
has also been suggested by the meta-analysis of Cortese et al 
based on the results of three trials that included probably 
blinded ratings.37
Another particularly important factor of influence is 
the specific titration procedure of stimulants that is used. 
Through suboptimal titration methods in trials, the treatment 
effects of stimulants may be underestimated compared to 
the clinical use of stimulants, leading to overestimating NF 
treatment effects in these trials. The RCT studies of Ogrim 
and Hestad27 and Geladé et al30 used optimally titrated stimu-
lant medication through a double-blind, placebo-controlled 
procedure and found medication to be superior to theta/beta 
in both behavioral and neurocognitive outcome measures. 
Other studies in the current review reported using standard 
dosages for MPH (1 mg/kg bodyweight) ranging across 
10–60 mg daily. The findings of the two RCTs with double-
blind optimal titration procedures do not support theta/beta 
NF as a standalone treatment for children or adolescents 
with ADHD.
As mentioned, the majority of studies in the present 
review did not exclude children based on psychiatric comor-
bidity, except for two studies.26,28 Not excluding patients 
based on psychiatric comorbidity enhances the generaliz-
ability of these studies, since comorbidity is a characteristic 
part of the clinical ADHD youth population.1 The two 
RCTs that excluded patients with comorbid disorders in the 
selection process found favorable results for theta/beta NF 
treatment,26,28 whereas the studies that did not exclude comor-
bidity found contrasting results. Even though two studies do 
not suffice to substantiate conclusions, it could suggest that 
children without comorbid disorders may be more receptive 
to theta/beta NF treatment, whereas children with ADHD and 
comorbid disorders (ie, psychiatrically more complex cases) 
may be in higher need of medication treatment. Another 
interpretation is that due to the high heterogeneity in ADHD, 
especially in those cases with comorbid disorders, different 
electrophysiological treatment targets should be considered 
depending on the exact presentation type of ADHD and 
the comorbid disorders, which might be another potential 
area of interest in future NF research. The current results 
indicate the need to reevaluate the rationale for the theta/
beta treatment protocol in ADHD. Emerging technological 
developments in the technique of NF seem promising and 
may aid in this regard, for example, through connectivity-
based NF, real-time-functional MRI-based NF or other imag-
ing methods with higher specificity and spatial resolution, 
allowing for more accurate targeting of compromised brain 
structures in ADHD, such as the right inferior prefrontal 
cortex.41
For NF to be clinically applicable, it is important to 
identify markers that differentiate between responders 
and nonresponders. Potential markers could range across 
neurophysiological parameters, environmental influences 
or psychological factors. One finding in the study of Ogrim 
and Hestad was that posttreatment theta activity did not dif-
fer between groups.27 The researchers suggested that theta 
may not be a good indicator of symptom change, but rather 
a marker for ADHD at a more basic level.27 However, the 
study of Janssen et al34 showed that children with increased 
baseline theta activity showed the greatest improvements, 
suggesting its potential utility in the identification of respond-
ers to theta/beta NF. Ogrim and Hestad suggested the P3 no 
go ERP as a potential marker for treatment response, which 
was increased in 8 out of 12 MPH responders.27 The P3 no 
go ERP is a specific ERP seen in EEG measures when the 
subject successfully reacts to a no go cue during cognitive 
tasks. The presence of the P3 no go ERP in EEG measures 
is assumed to reflect inhibitory control.42 In another publica-
tion, Janssen et al35 further investigated the P3 no go ERP and 
found that amplitudes only increased in the stimulant group 
and not in the theta/beta group, suggesting its potential util-
ity as a predictor of medication response, but less utility as 
a predictor of successful theta/beta treatment.35
To conclude, it appears that when only trials are consid-
ered that include probably blinded ratings or those that are 
sham-NF or semi-active controlled or those that employed 
optimally titration procedures, the findings do not support 
theta/beta NF as a standalone treatment for children or 
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adolescents with ADHD. However, when used in combina-
tion with medication, theta/beta NF may decrease medication 
dosage in children who already use medication to treat their 
ADHD symptoms and has additive treatment effects on top 
of stimulant medication. There seems to be an unidentified 
group of patients who may benefit from NF treatment, also 
after 6-month follow-up, possibly those without comorbid 
disorders, those with higher baseline theta, those with low 
response to stimulant medication and those who are more 
prone to experience side effects due to stimulants. Thus, 
based on the current state of the art, the current review 
concludes that the present role of theta/beta NF in treating 
children diagnosed with ADHD should be considered as 
complementary in a multimodal treatment approach, indi-
vidualized to the needs of the child, and may be considered 
a viable alternative to stimulants for a specific group of 
patients. NF is a relatively expensive treatment, and it is 
essential to expand our knowledge about patients who may 
benefit from this treatment. Future research should prioritize 
the following: the identification of markers that differentiate 
responders from nonresponders to NF treatment, the potential 
of NF to decrease stimulant dosage, the standardization of 
NF treatment protocols and the identification of the most 
favorable neurophysiological treatment targets.
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